Skip to content
MarketScale
‹ Back to Press ReleasesPress Releases

NCC 2026: CooperVision Research Supports a Lifetime of Clear, Comfortable Contact Lens Wear

CooperVision will actively participate in the 2026 Netherlands Contact Lens Congress (NCC), showcasing a variety of scientific papers and posters. Their research aims to support the continued development of contact lenses that provide clear and comfortable wear over a lifetime. The presentations will be part of the British Contact Lens Association's scientific stream.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from CooperVision on MarketScale.

By MarketScale Newsroom · Contact LensMyopia ControlPresbyopiaClinical Research
Share

Rochester, NY, CooperVision will present a range of scientific papers and posters in the British Contact Lens Association (BCLA) scientific stream at the 2026 Netherlands Contact Lens Congress (NCC) that demonstrates how evidence-based care and continuous innovation support clear, comfortable contact lens wear across every stage of life. The conference takes place March 8-9 in Veldhoven, Netherlands.

"At CooperVision, our commitment to helping improve the way people see each day means developing advanced contact lens designs and modalities that evolve with their vision needs," said Marcella McParland, MCOptom, FAAO. FIACLE, FBCLA, Senior Director Professional Affairs, EMEA, CooperVision. "The research we are sharing at NCC drives better understanding of wearer satisfaction, new fit adaptation, and prescribing patterns. These insights help eye care professionals confidently support patients from their very first contact lens experience through presbyopia."

Among the research highlights is an investigator initiated paper that examines the transition from a single vision contact lens to the dual focus design of MiSight® 1 day for myopia control, which found that young adults report comparable vision quality and comfort within six months. The findings underscore the importance of the practitioner managing patient expectations for comfort and vision quality during the adaptation period.*

Addressing the broader patient population, another paper validates that modern spherical contact lens designs, including MyDay®, Biofinity®, and Biofinity Energys® brands, continue to meet the everyday needs of new and experienced wearers in areas such as comfort, vision, and overall performance. CooperVision-delivered posters compare practitioner and consumer perspectives about remote eye care and explore new and lapsed contact lens wearer motivations and decision-making that expose specific opportunities for trial and adoption.

Moving along the wear continuum to presbyopia, additional CooperVision-supported research showcased at NCC includes three multifocal contact lens studies. One suggests opportunities for more proactive fitting for early presbyopic patients as well as closer alignment with fitting guide recommendations. Others illustrate the encouraging satisfaction rates of hydrogel multifocal wearers refit into a silicone hydrogel material and new and habitual contact lens wearers fit for the first time into a multifocal contact lens.

Further information about the studies is available at Abstracts 2026 - Nederlands Contactlens Congres. Held biennially, NCC is attended by thousands of eye care professionals, educators, researchers, and manufacturers from the Netherlands, Europe, and around the globe. For more information on the 2026 sessions and speakers, visit contactlenscongress.com.

*The investigator-initiated studies are conducted independently and are not controlled by CooperVision. CooperVision does not endorse any off-label use of its products.

About CooperVision

About CooperVision CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com. About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Media contact

Mike McDougall, FAAO, APR, Fellow PRSA, McDougall Communications for CooperVision, mike@mcdougallpr.com, +1.585.434.2150

Featured companies

CooperVision

Part of this channel

CooperVision

News, updates, and expert insights from CooperVision.

Visit the channel →

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation in US manufacturing lags, with 80% of factories lacking automation tools. In contrast, medtech manufacturers are advancing with technologies like micro-molding and ultrasonic welding. This disparity highlights a growing gap in technology adoption across different sectors.

  • 0180% of US factories have no automation.
  • 02Medtech manufacturers are investing in automation technologies.
  • 03There's an increasing divide in technology adoption across industries.

Jul 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512